Vale SA
VALE
D.R. Horton
DHI
Taylor Morrison Home
TMHC
Petroleo Brasileiro SA Petrobras
PBR
Ecopetrol
EC
US Stock MarketDetailed Quotes
VIR Vir Biotechnology
- 6.930
- -0.075-1.07%
Close Mar 18 16:00 ET
- 6.930
- 0.0000.00%
Post 16:39 ET
950.40MMarket Cap-1.81P/E (TTM)
7.147High6.745Low1.44MVolume6.910Open7.005Pre Close10.04MTurnover1.57%Turnover RatioLossP/E (Static)137.14MShares14.45052wk High0.83P/B638.31MFloat Cap6.56052wk Low--Dividend TTM92.11MShs Float141.010Historical High--Div YieldTTM5.74%Amplitude6.560Historical Low6.961Avg Price1Lot Size
About Vir Biotechnology Company
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Company Profile
SymbolVIR
Company NameVir Biotechnology
Listing DateOct 11, 2019
Issue Price20.00
Founded2016
CEODr. Marianne De Backer, PhD
MarketNASDAQ
Employees408
Fiscal Year Ends12-31
Address1800 Owens Street,Suite 900
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94158
Phone1-415-906-4324
Websitehttp://www.vir.bio
Company Executives
- Name
- Position
- Salary
- Dr. Marianne De Backer, PhD
- Chief Executive Officer and Director
- 39.49M
- Sasha Damouni Ellis
- Executive Vice President and Chief Corporate Affairs Officer
- --
- Jason O'Byrne
- Executive Vice President and Chief Financial Officer
- --
- Brent Sabatini
- Senior Vice President and Chief Accounting Officer
- --
- Jeffrey Calcagno, M.D.
- Executive Vice President and Chief Business Officer
- 4.54M
- Jennifer Towne
- Executive Vice President and Chief Scientific Officer
- --
- Dr. Vicki L. Sato, PhD
- Chairman of the Board
- --
- Dr. George A. Scangos,PhD
- Director
- 338.20K
- Dr. Ramy Farid, PhD
- Independent Director
- --
- Saira Ramasastry, M.Phil,M.S.
- Independent Director
- --
- Professor Dr. Norbert W. Bischofberger, PhD
- Independent Director
- --
- Janet Napolitano
- Independent Director
- --
- Jeffrey S. Hatfield
- Independent Director
- --
- Robert Taylor Nelsen
- Independent Director
- --
- Robert J. More
- Independent Director
- --
- Dr. Elliott Sigal, M.D.,PhD
- Independent Director
- --
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.